Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis.
Marjan AssefiKai-Uwe LewandrowskiMorgan LorioRossano Kepler Alvim Fiorellinull nullStefan LandgraeberAlireza SharafshahPublished in: Journal of personalized medicine (2023)
New game-changing drugs including Mavrilimumab, Iguratimod, Upadacitinib, Fenebrutinib, and nanoparticles may be crucial in controlling symptoms in poorly managed RA patients. Emerging therapeutic targets like Toll-like 4 receptors, NLRP3 inflammasome complexes, and mesenchymal stem cells can further transform RA therapy.
Keyphrases
- rheumatoid arthritis
- nlrp inflammasome
- mesenchymal stem cells
- disease activity
- end stage renal disease
- ejection fraction
- ankylosing spondylitis
- chronic kidney disease
- prognostic factors
- interstitial lung disease
- high dose
- bone marrow
- peritoneal dialysis
- depressive symptoms
- umbilical cord
- low dose
- emergency department
- physical activity
- sleep quality
- replacement therapy
- network analysis